Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population

참고문헌 (8)

1. Lee CM, "Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings", Hepatology (2023)[DOI]
2. Yoon EL, "Waiting for the changes after the adoption of steatotic liver disease", Clin Mol Hepatol, 29, pp.844~850 (2023)
3. Yoo JJ, "Recent research trends and updates on nonalcoholic fatty liver disease", Clin Mol Hepatol, 25, pp.1~11 (2019)
4. Graupera I, "Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population", Clin Gastroenterol Hepatol, 20, pp.2567~2576 (2022)
5. Park H, "Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era", Hepatol Res, 52, pp.247~254 (2022)
6. Park H, "Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting", Hepatol Commun, 7, pp.e0249~ (2023)
7. Moon SY, "Proposal of a novel serological algorithm combining FIB-4 and serum M2BPGi for advanced fibrosis in nonalcoholic fatty liver disease", Gut Liver, 18, pp.283~293 (2024)
8. Kim M, "Sequential combination of FIB-4 followed by M2BPGi enhanced diagnostic performance for advanced hepatic fibrosis in an average risk population", J Clin Med, 9, pp.1119~ (2020)

관련 논문AI추천